908 Devices Inc. (MASS) Q4 2025 Earnings Call Transcript

908 Devices Inc. (MASS) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 3, 2026

908 Devices Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Revenue Outlook

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter and full year ended December 31, 2025. Q4 2025 and Full Year 2025 Financial Highlights Revenue of $17.4 million for the fourth quarter 2025, increasing 21% compared to the fourth quarter 2024 Revenue of $56.2 million for the full year.

Business Wire • Mar 3, 2026

908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates

908 Devices Inc. (MASS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.32 per share a year ago.

Zacks Investment Research • Mar 3, 2026

908 Devices to Participate in Investor Conferences in March

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced it will participate in the following investor conferences. TD Cowen 46th Annual Healthcare Conference, Boston, MA Fireside chat on Wednesday, March 4 at 9:10 a.m. Eastern Time Leerink Global Healthcare Conference, Miami, FL Fireside chat on Monday, March 9 at 1:40 p.m.

Business Wire • Feb 24, 2026

908 Devices to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the fourth quarter and full year 2025 before market open on Tuesday, March 3, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “.

Business Wire • Feb 17, 2026

908 Devices Enhances MX908 Usability and Adds New Drug Targets

BURLINGTON, Mass.--(BUSINESS WIRE)-- #chemicalID--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces new capabilities for its handheld MX908 mass spectrometry device for trace chemical identification. These enhancements include an updated mission mode for hazardous vapor sampling and the addition of five priority drug targets, providing first responders with intelligence at the point of need for an informed, confident response. The MX908 mission mode.

Business Wire • Feb 5, 2026

908 Devices (MASS) Moves 19.2% Higher: Will This Strength Last?

908 Devices (MASS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Jan 21, 2026

908 Devices Announces Strong Preliminary Financial Results for Fourth Quarter and Full Year 2025

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced preliminary unaudited financial results for the quarter and full year ended December 31, 2025. Preliminary unaudited revenue for the fourth quarter of 2025 is approximately $17.2 million, compared to $14.3 million in the fourth quarter of 2024, reflecting reported gro.

Business Wire • Jan 20, 2026

908 Devices Inc. (MASS) Q3 2025 Earnings Call Transcript

908 Devices Inc. ( MASS ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Barbara Russo - VP of Marketing & Corporate Communications Kevin Knopp - Co-Founder, CEO, President & Director Joseph Griffith - CFO & Treasurer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Matthew Larew - William Blair & Company L.L.C., Research Division Brendan Smith - TD Cowen, Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Ladies and gentlemen, thank you for joining us, and welcome to the 908 Devices Third Quarter 2025 Financial Results Conference Call.

Seeking Alpha • Nov 10, 2025

908 Devices Reports Third Quarter 2025 Financial Results and Reiterates 2025 Revenue Outlook

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended September 30, 2025. “We are pleased with our year-to-date progress as we continue to build a more predictable and profitable business and bring our 908 Devices 2.0 vision to life,” said Kevin J. Knopp, CEO and Co-founder. “Revenue for the f.

Business Wire • Nov 10, 2025